{"id":9264,"date":"2024-12-03T10:51:37","date_gmt":"2024-12-03T09:51:37","guid":{"rendered":"https:\/\/www.seventure.fr\/?p=9264"},"modified":"2025-01-09T10:54:15","modified_gmt":"2025-01-09T09:54:15","slug":"gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/","title":{"rendered":"Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,106],"tags":[],"class_list":["post-9264","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-biotech-pharmaceuticals"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target | Seventure<\/title>\n<meta name=\"description\" content=\"Through this agreement, Gilead will gain access to Tubulis\u2019 proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Romane Brunet\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/\",\"url\":\"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/\",\"name\":\"Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2024-12-03T09:51:37+00:00\",\"dateModified\":\"2025-01-09T09:54:15+00:00\",\"author\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5\"},\"description\":\"Through this agreement, Gilead will gain access to Tubulis\u2019 proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5\",\"name\":\"Romane Brunet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"caption\":\"Romane Brunet\"},\"url\":\"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target | Seventure","description":"Through this agreement, Gilead will gain access to Tubulis\u2019 proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/","twitter_misc":{"Written by":"Romane Brunet"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/","url":"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/","name":"Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2024-12-03T09:51:37+00:00","dateModified":"2025-01-09T09:54:15+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"description":"Through this agreement, Gilead will gain access to Tubulis\u2019 proprietary Tubutecan and Alco5 platforms. The companies will collaborate to select the best technology to utilize, with Tubulis leading discovery and development efforts to design a Topoisomerase I inhibitor-based ADC candidate with superior biophysical properties and stability to address current treatment challenges such as durability and off-target toxicity.","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/gilead-and-tubulis-enter-into-exclusive-option-and-licence-agreement-to-develop-adc-candidate-for-select-solid-tumor-target\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5","name":"Romane Brunet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","caption":"Romane Brunet"},"url":"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=9264"}],"version-history":[{"count":3,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9264\/revisions"}],"predecessor-version":[{"id":9267,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9264\/revisions\/9267"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=9264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=9264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=9264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}